Clinical trials
Lymphoma, Large B-Cell, Diffuse trials in Turkey (Türkiye)
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Active, not recruiting | 10 |
| Recruiting | 8 |
| Terminated | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 5 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Genmab | 4 |
| Hoffmann-La Roche | 4 |
| Incyte Corporation | 3 |
| Janssen Research & Development, LLC | 3 |
| Novartis Pharmaceuticals | 2 |
| ADC Therapeutics S.A. | 1 |
| AbbVie | 1 |
| Acerta Pharma BV | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Large B-Cell, Diffuse | 39 |
| Lymphoma, Non-Hodgkin | 15 |
| Lymphoma | 11 |
| Lymphoma, Follicular | 11 |
| Lymphoma, Mantle-Cell | 10 |
| Recurrence | 9 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Neoplasms | 8 |
| Waldenstrom Macroglobulinemia | 8 |
| Lymphoma, B-Cell, Marginal Zone | 7 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.